Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study.

ABSTRACT:

Background

Patients with idiopathic pulmonary fibrosis (IPF) frequently have multiple comorbidities, which may influence survival but go under-recognised in clinical practice. We therefore report comorbidity, antifibrotic treatment use and survival of patients with IPF observed in the multi-national EMPIRE registry.

Methods

For this prospective IPF cohort, demographics, comorbidities, survival and causes of death were analysed. Comorbidities were noted by the treating physician based on the patient's past medical history or as reported during follow-up. Comorbidities were defined as prevalent when noted at enrolment, or as incident when recorded during follow-up. Survival was analysed by Kaplan-Meier estimates, log-rank test, and Cox proportional hazards models. Hazard ratio

SUBMITTER: Jovanovic DM 

PROVIDER: S-EPMC9145164 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature